AbbVie Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
Mailing Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
Phone
(847) 932-7900
Fiscal Year End
1231
EIN
320375147
Financial Overview
FY2025 FY
$61.16B
Revenue
$2.73
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 23, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
Annual Reports
10-K
February 20, 2026
- Strong growth from newer immunology drugs Skyrizi and Rinvoq, which successfully offset a significant portion of Humira's sales decline.
- Strategic acquisitions of ImmunoGen ($10.1 billion) and Cerevel Therapeutics ($8.7 billion) significantly expanded AbbVie's oncology and neuroscience pipelines.
Material Events
8-K
Other
January 7, 2026
High Impact
- AbbVie announced a significant $1.3 billion pre-tax expense in Q4 2025 for acquired IPR&D and milestone payments.
- This expense is expected to reduce reported profits per share by $0.71 for both GAAP and non-GAAP earnings.
Insider Trading
STRONG SELL
2 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.